Product
Botensilimab
Aliases
AGEN1181, anti-CTLA-4, Anti-CTLA-4
Name
Botensilimab
4 clinical trials
1 drug
9 indications
Indication
Advanced CancerIndication
Colorectal CancerIndication
MelanomaIndication
AngiosarcomaIndication
Endometrial CancerIndication
Fibrolamellar CarcinomaIndication
Non-small-cell Lung CancerIndication
Ovarian CancerIndication
Prostate CancerDrug
BotensilimabClinical trial
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor TherapyStatus: , Estimated PCD: 2028-05-01
Clinical trial
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced CancerStatus: Recruiting, Estimated PCD: 2026-12-01